- Home
- APPS vs PRTA Comparison
APPS vs PRTA Comparison
Compare APPS & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- PRTA
- Stock Information
- Founded
- APPS N/A
- PRTA 2012
- Country
- APPS United States
- PRTA Ireland
- Employees
- APPS N/A
- PRTA N/A
- Industry
- APPS Multi-Sector Companies
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- APPS Miscellaneous
- PRTA Health Care
- Exchange
- APPS Nasdaq
- PRTA Nasdaq
- Market Cap
- APPS 562.7M
- PRTA 472.1M
- IPO Year
- APPS N/A
- PRTA N/A
- Fundamental
- Price
- APPS $6.24
- PRTA $10.75
- Analyst Decision
- APPS Buy
- PRTA Buy
- Analyst Count
- APPS 3
- PRTA 9
- Target Price
- APPS $4.83
- PRTA $16.14
- AVG Volume (30 Days)
- APPS 2.6M
- PRTA 584.3K
- Earning Date
- APPS 11-04-2025
- PRTA 11-06-2025
- Dividend Yield
- APPS N/A
- PRTA N/A
- EPS Growth
- APPS N/A
- PRTA N/A
- EPS
- APPS N/A
- PRTA N/A
- Revenue
- APPS $503,443,000.00
- PRTA $10,341,000.00
- Revenue This Year
- APPS $10.64
- PRTA N/A
- Revenue Next Year
- APPS $11.24
- PRTA $602.32
- P/E Ratio
- APPS N/A
- PRTA N/A
- Revenue Growth
- APPS N/A
- PRTA N/A
- 52 Week Low
- APPS $1.18
- PRTA $4.32
- 52 Week High
- APPS $7.77
- PRTA $18.78
- Technical
- Relative Strength Index (RSI)
- APPS 50.11
- PRTA 63.31
- Support Level
- APPS $5.98
- PRTA $10.34
- Resistance Level
- APPS $6.92
- PRTA $10.82
- Average True Range (ATR)
- APPS 0.42
- PRTA 0.54
- MACD
- APPS -0.12
- PRTA -0.02
- Stochastic Oscillator
- APPS 15.29
- PRTA 54.81
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.